Suchergebnisse - "Faust, Saul N"

PubPharm (34)

1

Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection : A Randomized Clinical Trial

enthalten in: The Journal of pediatrics | 2024

von Kimberlin, D. | Aban, I. | Peri, K. | +22

2

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

enthalten in: The New England journal of medicine | 2023

von Drysdale, S. | Cathie, K. | Flamein, F. | +118

CommentIn: N Engl J Med. 2024 Mar 21;390(12):1152. - PMID 38507765

3

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3) : A randomised controlled trial

enthalten in: The Journal of infection | 2023

von Kelly, E. | Greenland, M. | de Whalley, P. | +31

4

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

5

Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) : an open-label, multicentre, randomised trial

enthalten in: The Lancet. Child & adolescent health | 2023

von Welzel, T. | Atkinson, A. | Schöbi, N. | +81

ErratumIn: Lancet Child Adolesc Health. 2023 Apr;7(4):e10. - PMID 36948662

6

Diagnosing acute bone and joint infection in children

enthalten in: The bone & joint journal | 2023

von Theologis, T. | Brady, M. | Hartshorn, S. | +2

7

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST) : a multicentre, blinded, phase 2, randomised trial

enthalten in: The Lancet. Infectious diseases | 2022

von Munro, A. | Feng, S. | Janani, L. | +153

CommentIn: Lancet Infect Dis. 2022 Aug;22(8):1092-1093. - PMID 35550263

8

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

9

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial

enthalten in: Clinical and translational science | 2022

von Hodgson, S. | Iveson, P. | Larwood, J. | +17

10

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) : a single-blind, randomised, controlled, phase 2/3 trial

enthalten in: Lancet (London, England) | 2021

von Ramasamy, M. | Minassian, A. | Ewer, K. | +162

ErratumIn: Lancet. 2021 Dec 19;396(10267):1978. - PMID 33341142